➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKesson
Merck
Boehringer Ingelheim
McKinsey

Last Updated: August 15, 2020

DrugPatentWatch Database Preview

TOTACILLIN-N Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Totacillin-n patents expire, and when can generic versions of Totacillin-n launch?

Totacillin-n is a drug marketed by Glaxosmithkline and is included in two NDAs.

The generic ingredient in TOTACILLIN-N is ampicillin sodium. There are seventy drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ampicillin sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Totacillin-n

A generic version of TOTACILLIN-N was approved as ampicillin sodium by SANDOZ on February 19th, 1987.

  Start Trial

Summary for TOTACILLIN-N
Drug patent expirations by year for TOTACILLIN-N

US Patents and Regulatory Information for TOTACILLIN-N

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline TOTACILLIN-N ampicillin sodium INJECTABLE;INJECTION 060677-004 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline TOTACILLIN-N ampicillin sodium INJECTABLE;INJECTION 060677-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline TOTACILLIN-N ampicillin sodium INJECTABLE;INJECTION 062727-002 Dec 19, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline TOTACILLIN-N ampicillin sodium INJECTABLE;INJECTION 060677-003 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline TOTACILLIN-N ampicillin sodium INJECTABLE;INJECTION 062727-001 Dec 19, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline TOTACILLIN-N ampicillin sodium INJECTABLE;INJECTION 060677-005 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Mallinckrodt
Dow
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.